News

GlaxoSmithKline to limit payments it makes to US doctors to $150 000 a year

BMJ 2008; 337 doi: 10.1136/bmj.a2315 (Published 30 October 2008)
Cite this as: BMJ 2008;337:a2315

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Zosia Kmietowicz
  1. 1London

    GlaxoSmithKline is to limit the advisory payments and honorariums it offers to doctors in the United States to $150 000 (£96 000; €120 000) a doctor a year. The company has also said that it will publish the amount of money it offers to doctors “without exception,” although doctors’ names will not be published.

    Andrew Witty, chief executive of the company, told the Financial Times, “It’s appropriate that we have a limit on what we pay. In the past, whatever has happened has happened, but in the future there will be strict adherence to these caps, which will be clearer to everybody” (23 Oct, p 22).

    A spokeswoman for the company said that it had no plans to introduce a cap on payments …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular